Insulet Corporation Finalizes Consulting Agreement with Former CTO Mark Field

ACTON, Massachusetts — Insulet Corporation (Nasdaq: PODD) has entered into a Consulting Services Agreement with its former Chief Technology Officer, Mark Field, following his departure from the company effective March 14, 2025.

Under the terms of the agreement, which became effective on the same date as Mr. Field’s departure, he will serve as a consultant to Insulet through August 31, 2025. During this period, he has agreed to be reasonably available to the company and will receive compensation at a rate of $450 per hour.

Importantly, Mr. Field’s unvested equity awards under Insulet’s 2017 Stock Option and Incentive Plan will continue to vest throughout the consulting period.

Mr. Field's departure was originally disclosed in a Form 8-K filed on March 17, 2025. This amendment provides additional details regarding the compensation and terms of his ongoing advisory role with the company.

Insulet Corporation is a medical device company known for its Omnipod® Insulin Management System, offering innovative tubeless insulin pump technology for people living with diabetes.